Regeneron Pharmaceuticals (REGN.O) has indicated it anticipates exemption from upcoming U.S. pharmaceutical tariffs, signaling the biotech company may be close to finalizing a pricing arrangement with the Trump administration 1.
This optimism emerges as the administration rolled out industry-specific tariffs aimed at drugmakers lacking pricing agreements, potentially transforming competitive landscapes within the $213 billion U.S. pharmaceutical import sector.
Key Takeaways
- Regeneron expects to reveal Trump administration pricing agreement “near future”
- Company stands as final holdout among 17 targeted pharmaceutical companies
- Administration implements 100% tariffs for non-compliant manufacturers
Market Context and Tariff Framework
Among 17 major pharmaceutical companies that received correspondence from President Donald Trump in July, Regeneron remains the sole entity yet to finalize a most-favored-nation pricing deal 1. The administration declared Wednesday that firms lacking agreements will face 100% tariffs on patented drug imports, while companies with signed deals obtain three-year exemptions 2.
Sixteen other pharmaceutical leaders, including Pfizer, Johnson & Johnson, and Merck, have already concluded agreements incorporating price reductions and domestic manufacturing pledges. These arrangements mandate companies provide Medicaid programs international reference pricing access and engage with TrumpRx.gov, a direct-to-consumer platform 3.
Regeneron’s Strategic Position
The Tarrytown-headquartered firm stated it expects to reveal an agreement “in the near future” aimed at lowering prescription drug costs for government Medicaid programs and cash-paying consumers 1. Regeneron maintains production facilities in New York and Limerick, Ireland, providing operational flexibility for manufacturing arrangements.
The company’s optimism indicates advancing negotiations despite remaining the last major holdout. Industry experts highlight Regeneron’s $3.6 billion Tarrytown facility expansion as evidence of substantial U.S. manufacturing dedication, potentially bolstering its bargaining position 4.
Industry Impact and Compliance Challenges
The administration’s tariff framework generates substantial pressure for pharmaceutical firms to reorganize global operations. Major companies receive 120 days to declare compliance strategies, while smaller entities get 180-day extensions 2.
European manufacturers encounter specific difficulties, with tariffs lowered to 15% for producers from nations holding existing trade agreements, including key pharmaceutical exporters like Switzerland and Ireland. The policy excludes generic medications while focusing on innovative treatments, creating what industry associations describe as an illogical separation 5.
Broader Market Implications
Industry experts project the pharmaceutical sector could face up to $46 billion in additional import expenses if country-specific tariffs apply extensively throughout the industry. This represents substantial impact on sector operating margins, which may reach 40% for leading performers 6.
“We believe sustained tariffs would drive up U.S. drug prices for consumers, because even if companies were to redomicile manufacturing, it will take years and cost more than ex-U.S. manufacturing,” Leerink Partners analysts said in a research note 7.
Manufacturing and Pricing Strategy
The most-favored-nation structure demands companies synchronize U.S. prices with the second-lowest price among reference nations including Germany, France, and Switzerland. This generates complex obstacles for European pricing approaches, as firms might exit markets that could establish low reference prices 5.
Regeneron’s bifurcated manufacturing presence positions it favorably to satisfy both pricing obligations and domestic production standards. The company’s continuing Tarrytown expansion constitutes among the largest biotechnology manufacturing investments in New York state’s history.
Not investment advice. For informational purposes only.
References
1Reuters (April 2, 2026). “Regeneron says it expects to avoid new US pharma tariffs”. Reuters. Retrieved April 2, 2026.
2MarketScreener (April 2, 2026). “Regeneron says it expects to be exempt from the pharma tariffs”. MarketScreener. Retrieved April 2, 2026.
3Jacob White (January 8, 2026). “White House Signs Multiple Deals with Large Pharma on Drug Pricing, Tariffs”. DCAT Value Chain Insights. Retrieved April 2, 2026.
4Brian Buntz (September 30, 2025). “If you build it, tariffs won’t come: Pharma’s billion-dollar ultimatum”. Research & Development World. Retrieved April 2, 2026.
5Euractiv (January 20, 2026). “Small pharma companies brace for impact of Trump’s pricing policy”. Euractiv. Retrieved April 2, 2026.
6Vahid Karaahmetovic (April 3, 2025). “Pharma stocks up on US tariff exemptions but analyst flags a $46B import cost risk”. Yahoo Finance. Retrieved April 2, 2026.
7Alex Philippidis (March 28, 2025). “StockWatch: Will Trump Tariffs Return Biopharma Manufacturing to the U.S.?”. GEN – Genetic Engineering and Biotechnology News. Retrieved April 2, 2026.